Description
Scientific Director - Research to Practice (Remote)
Research To Practice (RTP) is a leading provider of continuing medical education (CME) programs that deliver expert perspectives on clinical research and emerging data in oncology and hematology. Founded and led by Dr. Neil Love, RTP is dedicated to translating complex clinical science into meaningful educational experiences that inform and elevate patient care.
We create engaging, evidence-based educational programs—live and digital—that feature thought leaders from around the world and provide clinicians with practical, real-world insights that drive better outcomes for patients with cancer.
Summary: The Scientific Director is a key member of RTP’s scientific team, responsible for developing high-quality CME content and educational strategy across all areas of oncology and hematology. Working directly with Dr. Neil Love and other scientific staff, the Scientific Director will design, oversee, and evaluate educational initiatives that align with RTP’s standards of excellence and impact.
This individual must bring deep scientific knowledge, editorial precision, and creative vision to the role, ensuring that every activity—whether a live symposium, digital module, or print monograph—is both scientifically rigorous and clinically relevant.
Key Responsibilities:
- Scientific Leadership & Program Development
- Collaborate with Dr. Neil Love and the RTP scientific team to develop CME programs covering a wide range of oncology and hematology topics.
- Independently design and execute all elements of CME programs, including:
- Gap analysis (needs assessment)
- Agenda and learning objectives
- Educational format and outcomes plan
- Alignment with RTP’s established style, tone, and scientific standards
- Write and review content for educational materials, ensuring accuracy, balance, and compliance with ACCME guidelines.
- Live program management including:
- Faculty development/selection and interfacing with faculty on-site
- Slide set and educational development (outcomes assessment, CME information, etc.)
- Analyze assessment data and prepare presentations summarizing outcomes and insights for executive leadership.
- Manage 1-2 junior level scientific staff
Qualifications
- Advanced scientific or clinical degree (PharmD, PhD, MD, or MS) required.
- Minimum of 3+ years of experience in medical communications, CME, or related field—preferably with oncology focus.
- Demonstrated expertise in clinical oncology and an ability to interpret complex clinical data.
- Experience conducting needs assessments, developing learning objectives, and writing CME content.
- Strong understanding of ACCME standards, FDA regulations, and PhRMA code.
- Exceptional written and verbal communication skills, with meticulous attention to detail.
- Ability to thrive in a fast-paced, intellectually demanding environment with multiple ongoing projects.
- Travel Required 5 times per year to major scientific conferences
Why Join Research To Practice
- Collaborate directly with Dr. Neil Love and a respected team of oncology thought leaders.
- Shape education that meaningfully impacts how clinicians deliver cancer care.
- Join a mission-driven organization known for its scientific integrity, creativity, and influence in oncology CME.
- Flexible, collegial environment that values professional growth, innovation, and collaboration.
Similar jobs
Est. 140,000 USD
This position is based fully remote (working from home)! About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify effective, holistic, science-based str…
Est. 140,000 USD
About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify effective, holistic, science-based strategies to address their objectives through medical commu…
Est. 140,000 USD
About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify effective, holistic, science-based strategies to address their objectives through medical commu…
Est. 140,000 USD
About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify effective, holistic, science-based strategies to address their objectives through medical commu…
Est. 140,000 USD
About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify effective, holistic, science-based strategies to address their objectives through medical commu…
Est. 140,000 USD
About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify effective, holistic, science-based strategies to address their objectives through medical commu…
Est. 140,000 USD
This position can be based remotely (working from home) or at our headquarters in Stamford, CT. About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify…
This position is based fully remotely! About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify effective, holistic, science-based strategies to address…
Est. 120,000 USD
About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify effective, holistic, science-based strategies to address their objectives through medical commu…
Est. 140,000 USD
This position can be based remotely (working from home) or at our headquarters in Stamford, CT. About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify…
Est. 140,000 USD
This position can be based remotely (working from home) or at our headquarters in Stamford, CT. About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify…
Est. 140,000 USD
This position can be based remotely (working from home) or at our headquarters in Stamford, CT. About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify…
Est. 140,000 USD
**Apply to join Lockwood's Scientific Director Freelancer Community for both immediate and future assignments** About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device indust…
About Lockwood: Lockwood collaborates with clients in the pharmaceutical, biotech, and medical device industries to identify effective, holistic, science-based strategies to address their objectives through medical commu…
Est. 226,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 237,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 250,000 USD
Director, Drug Development Unit Tennessee Oncology Chattanooga, TN Job Details:
Est. 165,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 180,045 USD
For more than 25 years, Corcept has been singularly focused on the science of cortisol, a powerful hormone that when unregulated, can play a role in a broad range of diseases. Our commercial portfolio includes treatments…
Est. 184,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 160,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 184,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 184,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 184,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 274,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 396,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 237,500 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 317,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…
Est. 226,000 USD
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress…